Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
Total Valuation
Foghorn Therapeutics has a market cap or net worth of $191.86M. The enterprise value is $354.51M.
Market Cap$191.86M
Enterprise Value$354.51M
Share Statistics
Foghorn Therapeutics has 55.61M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55.61M
Owened by Insiders1.32%
Owened by Instutions45.40%
Financial Efficiency
Foghorn Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$201,803.571
Profits Per Employee-$773,392.857
Employee Count112
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Foghorn Therapeutics is -2.99. Foghorn Therapeutics’s PEG ratio is 0.09.
PE Ratio-2.99
PS Ratio11.46
PB Ratio-5.69
Price to Fair Value-5.69
Price to FCF-2.56
Price to Operating Cash Flow-2.58
PEG Ratio0.09
Income Statement
In the last 12 months, Foghorn Therapeutics had revenue of $22.60M and earned -$86.62M in profits. Earnings per share was -$1.66.
Revenue$22.60M
Gross Profit$20.27M
Operating Income-$100.28M
Pretax Income-$86.62M
Net Income-$86.62M
EBITDA-97.90M
Earnings Per Share (EPS)-1.66
Cash Flow
In the last 12 months, operating cash flow was -$100.41M and capital expenditures -$906.00K, giving a free cash flow of -$101.31M billion.
Operating Cash Flow-$100.41M
Free Cash Flow-$101.31M
Free Cash Flow per Share-$1.82
Dividends & Yields
Foghorn Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.22
52-Week Price Change-46.01%
50-Day Moving Average4.42
200-Day Moving Average6.25
Relative Strength Index (RSI)34.93
Average Volume (3m)127.07K
Important Dates
Foghorn Therapeutics upcoming earnings date is May 12, 2025, TBA.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Foghorn Therapeutics as a current ratio of 3.73, with Debt / Equity ratio of -0.82
Current Ratio3.73
Quick Ratio3.73
Debt to Market Cap0.14
Net Debt to EBITDA―
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Foghorn Therapeutics has paid $791.72K in taxes.
Income Tax$791.72K
Effective Tax Rate0.00%
Enterprise Valuation
Foghorn Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Foghorn Therapeutics has $243.75M in cash and marketable securities with $37.13M in debt, giving a net cash position of -$206.62M billion.
Cash & Marketable Securities$243.75M
Total Debt$37.13M
Net Cash-$206.62M
Net Cash Per Share-$3.72
Tangible Book Value Per Share-$0.83
Margins
Gross margin is 100.00%, with operating margin of -454.31%, and net profit margin of -383.24%.
Gross Margin100.00%
Operating Margin-454.31%
Pretax Margin-383.24%
Net Profit Margin-383.24%
EBITDA Margin-429.90%
EBIT Margin-443.70%
Analyst Forecast
The average price target for Foghorn Therapeutics is $11.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.50
Price Target Upside233.33%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-33.83%
EPS Growth Forecast27.89%